Biogen ANZ
在场
是其中之一......
- Forbes Global 2000 (#775);
- Fortune 500 (#401);
- Nasdaq 100;
- Russell 3000;
- S&P 500;
- TOB Iconic 10,000.
Biogen 是一家在股票代码 BIIB (US) 下上市的公司。
Biogen 在 9 个国家有直接业务。Biogen 拥有 9家子公司，其中包括 Biogen ANZ、Biogen BeLux 和 Biogen Canada。
他们在：
涉及Biogen的并购和融资。
- Biogen has announced the acquisition of HI-Bio (公布2024七月3号).
- Biogen 已收购 Reata Pharmaceuticals (公布2023九月29号).
- Biogen has announced the acquisition of Reata Pharmaceuticals (公布2023八月1号).
高管
查看带有其 2 名主要高管的组织结构图
Biogen ANZ 搜索最多的简介
高管在Biogen变化
- Michael McDonnell, Executive Vice President and Chief Financial Officer, 将于 20252月27 退休 (新闻发布的2024十月30号).
- Robin Kramer 曾任 Senior Vice President, Chief Accounting Officer, Head of Global Business Services and Treasury, 将于 20252月27 升职为 Chief Financial Officer (新闻发布的2024十月30号).
- Menelas PangalosMenelas Pangalos 将于202412月31作为 Director 加入公司 (新闻发布的2024九月12号).
创建提醒
跟踪 Biogen ANZ 的高管变动
生物技术
Biogen 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Genus (联合王国)。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Biogen ANZ 的最新新闻稿
- EISAI PRESENTS NEW FINDINGS ON LECANEMAB’S INVESTIGATIONAL SUBCUTANEOUS FORMULATION AND MODELING SIMULATION OF APOE4 GENOTYPE ON ARIA-E INCIDENCE AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2022 | Biogen
- The New England Journal of Medicine Publishes Positive Phase 2 Data on Litifilimab (BIIB059) in Cutaneous Lupus Erythematosus | Biogen
- FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS | Biogen
- Biogen to Report Second Quarter 2022 Financial Results July 20, 2022 | Biogen
- Biogen and Happify Health Collaborate to Support Multiple Sclerosis Patients on Digital Platform | Biogen
- European Patent Office Grants Patent Related to TECFIDERA® (Dimethyl Fumarate) | Biogen
- New Data Presented at Cure SMA Reveal Residual Unmet Needs in Young SMA Patients Treated With Gene Therapy and Suggest Further Potential of Using SPINRAZA® (nusinersen) | Biogen
- The Biogen Foundation and Community Lab Celebrates 20 Years of Serving our Communities | Biogen
- Biogen Withdrawal from the Jefferies Healthcare Conference | Biogen
- Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease | Biogen
- View more press releases Close
关于 Biogen ANZ 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 David Henderson 
